Vitamin D for Cancer Prevention: Global Perspective
Purpose
Higher serum levels of the main circulating form of vitamin D, 25-hydroxyvitamin D (25(OH)D), are associated with substantially lower incidence rates of colon, breast, ovarian, renal, pancreatic, aggressive prostate and other cancers.
Methods
Epidemiological findings combined with newly discovered mechanisms suggest a new model of cancer etiology that accounts for these actions of 25(OH)D and calcium. Its seven phases are disjunction, initiation, natural selection, overgrowth, metastasis, involution, and transition (abbreviated DINOMIT). Vitamin D metabolites prevent disjunction of cells and are beneficial in other phases.
Results/Conclusions
It is projected that raising the minimum year-around serum 25(OH)D level to 40 to 60 ng/mL (100–150 nmol/L) would prevent approximately 58,000 new cases of breast cancer and 49,000 new cases of colorectal cancer each year, and three fourths of deaths from these diseases in the United States and Canada, based on observational studies combined with a randomized trial. Such intakes also are expected to reduce case-fatality rates of patients who have breast, colorectal, or prostate cancer by half. There are no unreasonable risks from intake of 2000 IU per day of vitamin D3, or from a population serum 25(OH)D level of 40 to 60 ng/mL. The time has arrived for nationally coordinated action to substantially increase intake of vitamin D and calcium.
Key Words: Vitamin D, Breast Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Dose-Response, Calcium, Etiology, Prevention, Treatment, Survival
Selected Abbreviations and Acronyms: 25(OH)D, 25-hydroxyvitamin D, UVB, ultraviolet B, NHANES III, Third National Health and Nutrition Examination Survey, CI, confidence interval, VDR, vitamin D receptor, PLCO, Prostate, Lung, Colon and Ovarian [cancer screening project], RCT, randomized controlled trial, DINOMIT, disjunction–initiation–natural selection–overgrowth–metastasis–involution–transition, NAS-IOM, National Academy of Science–Institute of Medicine, AI, adequate intake, UL, upper limit
To access this article, please choose from the options below
PII: S1047-2797(09)00105-7
doi:10.1016/j.annepidem.2009.03.021
Published by Elsevier Inc.
